Zacks Investment Research
05 Aug 2026, 16:55 UTC · 1h ago
AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 16:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Amgen reported Q2 2026 adjusted earnings of $6.29 per share and total revenues of $10.1 billion, beating consensus estimates of $5.60 and $9.44 billion respectively. — A double beat on both top and bottom lines typically triggers a positive short-term reaction in equity prices.
+0.60Repatha sales surged 37% to $953 million and Evenity sales climbed 38% to $714 million, both exceeding analyst estimates. — Strong growth in key product lines indicates successful market penetration and revenue diversification.
+0.50Prolia and Xgeva revenues fell 32% and 34% respectively due to patent expirations in 2025 and the launch of global biosimilars. — Significant erosion of legacy best-selling drugs creates a long-term revenue gap that new products must fill.
-0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Otezla sales declined 21% to $491 million, missing the consensus estimate of $562 million. — A miss on a specific product estimate suggests unexpected competitive pressure or pricing headwinds.
-0.30Tezspire sales rose 42% to $486 million, marginally exceeding consensus estimates. — Steady growth in a partnership asset provides a secondary positive revenue stream.
+0.20Which stocks this story touches
Reported Q2 2026 earnings and revenue that beat consensus estimates, with strong growth in Repatha and Evenity sales.
Mentioned as a partner in the growth of Tezspire sales, which exceeded estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
